http://www.nccn.org The National Comprehensive Cancer Network (NCCN), an alliance of the world's leading cancer centers, is an authoritative source of comprehensive cancer care information that strives to insure the quality of cancer care and advance clinical research. Through the collaborative expertise of its member institutions, the NCCN develops, evaluates, and disseminates practice guidelines to support health professionals and patients in making informed treatment decisions. en-us Copyright 2008 NCCN Tue, 21 May 2013 00:00 GMT Tue, 21 May 2013 00:00 GMT http://www.nccn.org/images/nccn_logo.gif http://www.nccn.org 60 http://www.nccn.org/about/news/newsinfo.asp?NewsID=93 -- NCCN to study clinical applications of therapies in treatment of breast, gynecological, and other forms of cancer -- [PEAPACK, NJ] – Pharmacia Corporation today announced it has provided a $3.15 million grant to the National Comprehensive Cancer Network (NCCN) for the development and review of clinical oncology research protocols and trials in breast, gynecological and other forms of cancer. The grant will provide funding for clinical research to identify treatment advances that improve p... Tue, 1 Jan 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=30 Nineteen of the world`s leading cancer centers align to advance cancer treatment ROCKLEDGE, PA, June 5, 2002 - The National Comprehensive Cancer Network (NCCN) announces the launch of its Clinical Trials Network (CTN), a new strategy for advancing cancer therapies through clinical trials to improve patient care. A national, centralized infrastructure, CTN facilitates the initiation of clinical trials by ... Wed, 5 Jun 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=24 ROCKLEDGE, PA, November 5, 2002 – The National Comprehensive Cancer Network (NCCN) today announced changes made to their Web site (www.nccn.org) which will allow physicians to more easily locate clinical trials. Physicians seeking new treatments for their patients with cancer often turn to clinical trials for answers. These research studies include trials testing new treatments, such as a new cancer drug or a new combination of drugs, new approaches to surgery or radiation therapy, or new ther... Tue, 5 Nov 2002 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=20 ROCKLEDGE, PA, February 20, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, is very pleased to announce the awarding of $1,886,237 in research grants provided through the NCCN Clinical Trials Network (CTN). “NCCN’s Clinical Trials Network, a program devoted to facilitating the development of promising new therapeutics to improve patient outcomes, is very pleased to offer research funding to support investigator-initiated... Thu, 20 Feb 2003 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=51 JENKINTOWN, Pa., June 13, 2005 — William T. McGivney, Ph.D., CEO of the National Comprehensive Cancer Network (NCCN), announces that Diane E. Paul, MS, RN, has joined NCCN as Vice President, Clinical Trials Network. In this role, Paul will be responsible for developing a centralized, standardized infrastructure for the conduct of clinical trials among NCCN’s 19 member institutions. “This network will be of interest to pharmaceutical/biotechnology companies for the conduct of their trials. And... Mon, 13 Jun 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=57 JENKINTOWN, Pa., October 31, 2005 — The National Comprehensive Cancer Network (NCCN) announced that it has entered into a collaboration with Roche Laboratories, Inc. to develop and review ongoing oncology research protocols and trials examining Xeloda® (capecitabine) in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers. “NCCN’s mission is to improve cancer care by studying and evaluating new ... Mon, 31 Oct 2005 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=81 Funding will support innovative cancer research JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors. “NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology prac... Tue, 5 Sep 2006 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=123 JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman. Cetuximab, also known by its brand name ERBITUX®, is current... Thu, 15 Nov 2007 00:00 GMT http://www.nccn.org/about/news/pdf/AO990-266534.pdf ... Tue, 7 Oct 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=195 NCCN has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study. November 24, 2008 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN... Mon, 24 Nov 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=196 NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc... Mon, 1 Dec 2008 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=199 NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding. January 15, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... Thu, 15 Jan 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=211 The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer. April 29, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCC... Wed, 29 Apr 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=219 NCCN is holding the NCCN Oncology Research Best Practices Conference™, an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 – 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical consideration... Mon, 14 Sep 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=230 NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 10, 2009 FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... Tue, 10 Nov 2009 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=252 Identifying clinical trial benchmarking metrics and best practices at NCCN Member Institutions is the focus of a recent survey conducted by the National Comprehensive Cancer Network® (NCCN®). A poster presentation of the survey analysis will be featured at the 2010 ASCO Annual Meeting on June 7, 2010. June 4, 2010 FORT WASHINGTON — Clinical research is at the heart of National Comprehensive Cancer Network® (NCCN®) center operations, as it constitut... Fri, 4 Jun 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=255 NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. July 27, 2010 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical stud... Tue, 27 Jul 2010 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=260 NCCN recently received a $2.1 million research grant from Pfizer to gain further insights into the use of the investigational compound Axitinib in various tumor types. Investigators from NCCN Member Institutions are eligible to apply for the research funding. November 30, 2010 FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clin... Tue, 30 Nov 2010 00:00 GMT http://www.nccn.org/about/news/pdf/NCCN_SNM Partnership_release.pdf ... Tue, 8 Mar 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=282 NCCN has established the NCCN Specialized Imaging Research Consortium, a new initiative of the NCCN Oncology Research Program, to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies. FORT WASHINGTON, PA — Imaging plays an important role in clinical cancer care, and the increasing availability and use of advanced imaging methods have created a need for expertise in such techniques in order to guide their appropria... Fri, 27 May 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=287 The NCCN Oncology Research Program received $2.1 million in research funding from Pfizer, Inc. to support research at NCCN Member Institutions in order to gain further insight into the use of axitinib in various tumor types. FORT WASHINGTON, PA — The National Comprehensive Cancer Network®`s (NCCN®`s) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Axitinib Request f... Tue, 5 Jul 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=294 The NCCN Oncology Research Program received $4 million in research funding from GlaxoSmithKline to support research at NCCN Member Institutions in order to evaluate the effectiveness of ofatumumab (Arzerra®, GlaxoSmithKline) in hematologic malignancies and pazopanib (Votrient™, GlaxoSmithKline) in the treatment of solid tumors. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded... Wed, 31 Aug 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=302 NCCN recently received $4 million in the form of two research grants from GlaxoSmithKline to gain further insights into GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor, both promising therapies in the treatment of advanced melanoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarde... Tue, 11 Oct 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=307 NCCN recently received a $2 million research grant from Boehringer Ingelheim Pharmaceuticals, Inc. to gain further insight into the use of the investigational compound Afatinib (BIBW 2992) in solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pha... Thu, 10 Nov 2011 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=309 NCCN recently received a research grant from AVEO Pharmaceuticals and Astellas Pharma, Inc. to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has e... Thu, 16 Feb 2012 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=318 The NCCN Oncology Research Program (ORP) has qualified seven sites from Fox Chase Cancer Center, Seattle Cancer Care Alliance, and University of Alabama at Birmingham as part of its Affiliate Research Project (ARP). The ARP is dedicated to improving patient outcomes and advancing clinical research through collaboration with NCCN, NCCN Member Institutions, and community-based affiliate networks. FORT WASHINGTON, PA – The NCCN Affiliate Research Project (ARP), developed by the NCCN ... Tue, 10 Jul 2012 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=323 The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate and define clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced mela... Thu, 6 Sep 2012 00:00 GMT http://www.nccn.org/about/news/newsinfo.asp?NewsID=326 The NCCN Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib as a result of funding through the AVEO/Astellas collaboration. FORT WASHINGTON, PA – The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These gr... Mon, 15 Oct 2012 00:00 GMT